Liminal BioSciences stock (CA53272L1031): what’s next after its go?private deal?

Liminal BioSciences has been taken private by Structured Alpha LP, ending its Nasdaq listing and changing the story for equity investors. What remains of the equity case, and why does the company still matter for biotech watchers in North America?

Liminal BioSciences has undergone a major change in its capital?market profile after completing a go?private transaction with Structured Alpha LP in 2023, which resulted in the company’s delisting from Nasdaq and the Toronto Stock Exchange, according to Liminal BioSciences investor relations as of 10/18/2023.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Liminal BioSciences
• Sector/industry: Biotechnology / drug discovery
• Headquarters/country: Laval, Canada
• Core markets: North America and global biotech partnerships
• Key revenue drivers: Out?licensing of R&D programs and potential milestone payments
• Home exchange/listing venue: Previously Nasdaq and TSX (now private)
• Trading currency: Previously USD and CAD before going private

Liminal BioSciences: core business model

Liminal BioSciences is a clinical?stage biotechnology company focused on small?molecule therapeutics targeting G?protein?coupled receptors and other validated pathways, with an emphasis on fibrotic and inflammatory diseases. The company has reoriented its portfolio over the years from plasma?derived therapies toward proprietary drug discovery platforms, according to Liminal BioSciences company information as of 03/15/2024.

The business model centers on advancing a pipeline of candidates through early and mid?stage development and creating value either via internal progression or partnerships with larger pharmaceutical companies. This approach is common in the biotech sector, where smaller innovators depend on licensing deals, co?development agreements, and potential milestone and royalty streams rather than large, recurring product sales at an early stage of their corporate life cycle.

Over time, Liminal BioSciences has refined its asset portfolio, divesting non?core plasma?related activities and concentrating on small?molecule R&D programs in areas such as idiopathic pulmonary fibrosis and other fibrotic conditions. This shift mirrors a broader industry trend, as many companies move from capital?intensive manufacturing operations toward more focused discovery and development platforms, which can be scaled through partnerships while limiting fixed?cost exposure.

Main revenue and product drivers for Liminal BioSciences

As an R&D?driven biotech player, Liminal BioSciences historically generated limited product revenue and relied instead on financing transactions and collaboration income. Potential future value is tied predominantly to the success of investigational drug candidates and the ability to secure licensing agreements with larger pharmaceutical groups. These agreements can provide upfront payments, research funding, clinical and regulatory milestones, and royalties on net sales if programs reach the market.

Among its key scientific focus areas, Liminal BioSciences has highlighted GPR84 and OXER1 antagonists for inflammatory and fibrotic diseases in its pipeline communications, according to Liminal BioSciences pipeline overview as of 03/15/2024. Targeting such receptors aims to modulate immune responses and fibrotic pathways, potentially addressing conditions with high unmet medical need where existing therapies often provide only partial symptom control.

For a private biotech such as Liminal BioSciences, near?term financial performance is closely linked to cost discipline and access to capital rather than recurring sales. R&D spending, clinical?trial execution, and intellectual?property development are the main cash?use drivers. On the upside, a single successful licensing transaction or positive clinical milestone can significantly change the financial profile, while setbacks in trials or delays in partnering can have the opposite effect.

In the years preceding its go?private transaction, Liminal BioSciences recorded net losses typical for a clinical?stage biotech, reflecting substantial R&D investment and limited commercial revenue, according to its historical financial statements in the annual report for the year ended 12/31/2022, published on 03/31/2023 on the investor relations site. That backdrop provides context for why the company’s strategic options, including a potential sale or privatization, came into focus for shareholders and management.

Impact of the go?private transaction on former shareholders

The go?private process was driven by a plan of arrangement under Canadian corporate law, through which Structured Alpha LP, an entity controlled by long?time backer Thomvest Asset Management, acquired all outstanding common shares of Liminal BioSciences not already owned by it. The transaction was announced in July 2023 and completed in October 2023, resulting in minority shareholders receiving cash consideration per share, according to Liminal BioSciences investor relations as of 07/05/2023.

Upon completion of the arrangement, Liminal BioSciences applied for the delisting of its shares from Nasdaq and the Toronto Stock Exchange and also initiated the process to cease to be a reporting issuer under applicable Canadian securities laws, as stated in the closing announcement, according to Liminal BioSciences investor relations as of 10/18/2023. As a result, the stock is no longer available for regular trading on public exchanges, and former shareholders who did not tender or otherwise receive consideration in time have to rely on the terms of the arrangement for any remaining claims.

For US and European retail investors, this means that Liminal BioSciences is no longer an actively tradable equity on major exchanges, although some legacy positions may still sit in portfolios and custodial accounts. These positions effectively represent interests in a private company with no ready public market and are subject to the rights and procedures laid out in the acquisition documentation. This situation underscores the importance of monitoring corporate actions such as privatizations, which can materially alter liquidity and price discovery for a stock.

The rationale for going private, as described by the company and its acquirer, included simplifying the corporate structure, reducing the costs and administrative burden associated with public reporting, and providing management with greater strategic flexibility in pursuing long?term R&D programs without the short?term pressure of quarterly earnings expectations. For biotech firms with long development cycles, the ability to operate away from public?market volatility can be strategically attractive, even if it limits access to equity capital markets in the near term.

Strategic focus after delisting

Although detailed post?transaction updates have been less frequent given the company’s private status, the stated strategy at the time of the go?private move was to continue advancing Liminal BioSciences’ small?molecule pipeline and to explore partnership opportunities. The acquirer’s support was positioned as a way to secure funding for key programs and maintain continuity in scientific operations, according to statements in the arrangement announcement on 07/05/2023, as cited on the investor relations site.

In practical terms, delisting can allow management to adjust R&D priorities, timelines, and trial designs based on scientific merit and capital efficiency rather than market?driven expectations about news flow. However, this also reduces the volume of publicly available information, which can make it harder for outside observers to track progress on clinical programs, regulatory interactions, or potential partnering discussions with larger pharmaceutical companies.

For existing stakeholders, including Structured Alpha LP and affiliated entities, the key value drivers now are the scientific outcomes of the pipeline and the possibility of lucrative out?licensing or a future sale of assets. If any of the company’s investigational drugs advance successfully through later?stage trials and attract strong commercial partners, the eventual returns could justify the earlier decision to take the business private and bear the associated financial risks.

Why Liminal BioSciences still matters for US biotech watchers

Even though Liminal BioSciences is no longer listed on Nasdaq, its scientific work remains relevant for investors following the biotech and pharmaceutical sectors. The company operates in therapeutic areas that are of strong interest to large US?based drug makers, including fibrotic lung disease and chronic inflammatory conditions. Positive developments in these fields can influence deal activity, valuation benchmarks, and competitive dynamics for comparable public biotechs.

US investors who specialize in healthcare and biotech often monitor private companies as part of their broader research into therapeutic trends and partnering patterns. If Liminal BioSciences were to strike a major licensing deal with a US or global pharmaceutical company, or if its programs were acquired outright, such a move could affect sentiment around other developers pursuing similar targets. In that sense, the company’s trajectory can still provide signals for public?market investors, even if its own shares are not currently tradable.

Moreover, the case of Liminal BioSciences illustrates how smaller biotechs can shift between public and private ownership structures as they navigate capital markets and scientific milestones. For US retail investors, understanding these transitions is important when assessing the long?term risk profile of early?stage biotech stocks, which may ultimately be acquired or taken private at valuations that differ significantly from prior market prices.

Conclusion

Liminal BioSciences has transitioned from a publicly traded biotech to a privately held R&D company backed by Structured Alpha LP, closing an important chapter for former Nasdaq and TSX shareholders. The go?private deal removed the stock from public markets, changing the liquidity profile and making traditional equity analysis less relevant for retail investors. At the same time, the firm’s scientific focus on fibrotic and inflammatory diseases keeps it on the radar of biotech observers, as successful trials or partnerships could still influence comparable public names. For US investors, Liminal BioSciences now serves mainly as a case study in how small?cap biotechs navigate financing cycles, strategic reviews, and ownership changes along the path of drug development.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.